Business Context and Reporting Period
This Form 8-K Current Report was filed by Bark, Inc. on July 10, 2025. The filing addresses a regulatory notice received from the New York Stock Exchange (NYSE) regarding the Company's compliance with continued listing standards. The Company's common stock (BARK) and warrants (BARK WS) are listed on the NYSE.
Key Financial Metrics
This filing does not contain audited financial statements, revenue, profit, cash flow, or debt metrics. The only financial data point disclosed is the market price of the Company's common stock, which averaged less than $1.00 per share over the 30 trading-day period ended July 9, 2025.
Material Changes
- Listing Status: The Company received a formal Notice from the NYSE stating it is not in compliance with Section 802.01C of the Listed Company Manual due to the low average closing share price.
- Operational Impact: The Notice does not result in immediate delisting. Trading on the NYSE will continue during the cure period.
Guidance, Outlook, and Management Commentary
Management intends to cure the deficiency and regain compliance within the six-month cure period provided by NYSE rules. To achieve this, the Company must reach a closing share price of at least $1.00 and maintain an average closing price of at least $1.00 over a 30-trading-day period ending on the last trading day of any calendar month within the cure period. The Company is considering all available options, including a reverse stock split, subject to stockholder approval. Management stated the Notice is not anticipated to impact ongoing business operations or SEC reporting requirements.
Investor Verification Checklist
- Verify the current trading price of BARK stock relative to the $1.00 threshold.
- Monitor upcoming shareholder meetings for potential votes on a reverse stock split.
- Review the press release dated July 11, 2025 (Exhibit 99.1) for additional details on the Company's specific remediation plan.
- Track the Company's progress toward the 30-day average price requirement throughout the six-month cure period.